+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drugs in Development, 2021

  • PDF Icon

    Drug Pipelines

  • 128 Pages
  • September 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5451356
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Transthyretin (ATTR or Prealbumin or TBPA or TTR) pipeline Target constitutes close to 18 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Transthyretin - Drugs In Development, 2021, outlays comprehensive information on the Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics, complete with analysis b..y indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Transthyretin is a transport protein. It transports thyroid hormones in the plasma and cerebrospinal fluid, and also transports retinol (vitamin A) in the plasma. The diseases caused by mutations include amyloidotic polyneuropathy, euthyroid hyperthyroxinaemia, amyloidotic vitreous opacities, cardiomyopathy, oculoleptomeningeal amyloidosis, meningocerebrovascular amyloidosis and carpal tunnel syndrome. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 4 and 2 respectively. Similarly, the universities portfolio in Phase III and Phase I stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Cardiovascular, Gastrointestinal, Immunology and Infectious Disease which include indications Familial Amyloid Neuropathies, Amyloidosis, Familial Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Alzheimer's Disease, Cardiomyopathy, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Crohn's Disease (Regional Enteritis), Multiple Sclerosis, Rheumatoid Arthritis and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
  • The report reviews Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transthyretin (ATTR or Prealbumin or TBPA or TTR)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transthyretin (ATTR or Prealbumin or TBPA or TTR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Introduction

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Overview

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Development

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Assessment

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Companies Involved in Therapeutics Development

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drug Profiles

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Dormant Projects

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Discontinued Products

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by ADRx Inc, 2021
  • Pipeline by Akcea Therapeutics Inc, 2021
  • Pipeline by Alnylam Pharmaceuticals Inc, 2021
  • Pipeline by Autotac Bio Inc, 2021
  • Pipeline by BridgeBio Pharma Inc, 2021
  • Pipeline by Corino Therapeutics Inc, 2021
  • Pipeline by Covalent Bioscience Inc, 2021
  • Pipeline by Neurimmune Holding AG, 2021
  • Pipeline by Novo Nordisk AS, 2021
  • Pipeline by Precision Biosciences Inc, 2021
  • Pipeline by Proclara Biosciences Inc, 2021
  • Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Pipeline by Vera Therapeutics Inc, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ADRx Inc
  • Akcea Therapeutics Inc
  • Alnylam Pharmaceuticals Inc
  • Autotac Bio Inc
  • BridgeBio Pharma Inc
  • Corino Therapeutics Inc
  • Covalent Bioscience Inc
  • Neurimmune Holding AG
  • Novo Nordisk AS
  • Precision Biosciences Inc
  • Proclara Biosciences Inc
  • Regeneron Pharmaceuticals Inc
  • Vera Therapeutics Inc